Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 87,746,600
  • Shares Outstanding, K 1,095,600
  • Annual Sales, $ 22,871 M
  • Annual Income, $ -204,100 K
  • 36-Month Beta 0.26
  • Price/Sales 3.84
  • Price/Cash Flow 14.48
  • Price/Book 7.57

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.65 +7.29%
on 03/26/18
81.50 -1.73%
on 04/24/18
+5.33 (+7.13%)
since 03/23/18
3-Month
73.69 +8.69%
on 02/09/18
88.33 -9.33%
on 01/29/18
-4.21 (-4.99%)
since 01/24/18
52-Week
73.69 +8.69%
on 02/09/18
89.09 -10.10%
on 12/13/17
-3.33 (-3.99%)
since 04/24/17

Most Recent Stories

More News
Global Colorectal Cancer Diagnostic & Treatment Market 2018-2023 - A $17.84 Billion Market Opportunity Dominated by Celgene, Eli Lilly and Co, Amgen, and AstraZeneca - ResearchAndMarkets.com

The "Colorectal Cancer Diagnostic and Treatment Market - Forecasts from 2018 to 2023" report has been added to ResearchAndMarkets.com's offering.

LLY : 80.09 (-0.14%)
AMGN : 171.94 (-1.56%)
Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up

Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.

MRK : 60.09 (-0.27%)
LLY : 80.09 (-0.14%)
INCY : 62.35 (-8.50%)
PFE : 37.06 (+0.71%)
Eli Lilly (LLY) Tops Q1 Earnings & Sales, Ups 2018 View

Eli Lilly (LLY) beat estimates for both earnings and sales in Q1 and raised the guidance for 2018. Shares declined in pre-market trading.

LLY : 80.09 (-0.14%)
Is SPDR S&P Pharmaceuticals ETF (XPH) a Hot ETF Right Now?

Smart Beta ETF report for XPH

XPH : 40.76 (-0.44%)
JAZZ : 154.51 (-0.73%)
PJP : 61.80 (-0.71%)
IHE : 146.25 (-0.32%)
LLY : 80.09 (-0.14%)
AGN : 156.90 (-1.87%)
Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance

Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2018.

LLY : 80.09 (-0.14%)
AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies

Eli Lilly and Company (NYSE: LLY) announced today results from a post-hoc subgroup analysis which demonstrated efficacy of galcanezumab in patients with episodic and chronic migraine who previously failed...

LLY : 80.09 (-0.14%)
FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg...

LLY : 80.09 (-0.14%)
INCY : 62.35 (-8.50%)
Global CNS Market Analysis 2018 With AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson & Pfizer Leading the Market - ResearchAndMarkets.com

The "Analyzing the Global CNS Market 2018" report has been added to ResearchAndMarkets.com's offering.

JNJ : 126.19 (-0.50%)
LLY : 80.09 (-0.14%)
GSK : 40.64 (+0.77%)
Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN

Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.

JNJ : 126.19 (-0.50%)
LLY : 80.09 (-0.14%)
NVS : 76.99 (-0.79%)
AMGN : 171.94 (-1.56%)
BIIB : 262.15 (+1.10%)
Elanco Announces Addition of Chief Financial Officer

Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), named Christopher Jensen as senior vice president and chief financial officer (CFO), joining Elanco's Leadership Team and reporting...

LLY : 80.09 (-0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 82.75
1st Resistance Point 81.42
Last Price 80.09
1st Support Level 78.84
2nd Support Level 77.59

See More

52-Week High 89.09
Fibonacci 61.8% 83.21
Fibonacci 50% 81.39
Last Price 80.09
Fibonacci 38.2% 79.57
52-Week Low 73.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar